Weekly Digest - May 2025
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - May 2025
13 May 2025: LigaChem Biosciences partners with Y Biologics for antibody technology
- LigaChem has secured exclusive global rights to develop antibody-drug conjugates (ADCs) using a novel antibody from Y Biologics, targeting a highly expressed antigen in solid tumors
- The antibody demonstrates significantly higher cellular internalization rates compared to previously commercialized monoclonal antibodies for this target, potentially increasing ADC efficacy
- LigaChem plans to develop immune-modulating ADCs (AICs) incorporating in-house developed immune modulators, such as STING agonists, as payloads, aiming to enhance the tumor microenvironment’s immune activity
- The collaboration includes the potential to expand into dual-payload ADCs by combining immune-modulating payloads with cytotoxic agents, potentially increasing therapeutic efficacy
